ClinicalTrials.gg
Not yet recruitingNCT04690608ResistantUpdated Mar 5, 2024

Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy

An Early Phase 1 interventional study of Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1 in Retinal Edema, sponsored by Tanta University. Not yet recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Tanta University · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Sex
All
01

Study summary

Prospective interventional study on 60 eyes of resistant diabetic macular edema and central retinal vein occlusion that will receive suprachoroidal injection of Triamcinolone Acetonide (SCTA).

Read the detailed description
  • Prospective non randomized interventional study on 60 eyes of 40 patients with previously diagnosed macular edema secondary to type 1 or 2 diabetes mellitus and 60 eyes with central retinal vein occlusion will be included.
  • The study will be conducted from January 2021 to June 2021.
  • For transition to suprachoroidal injection of Triamcinolone Acetone (TAAC) a diagnosis of resistant DME is required.
  • Inclusion criteria:

Patients fulfilling one or more of the following criteria will be considered to have resistant diabetic macular edema (DME) after at least 3 consecutive monthly anti vascular endothelial growth factor (VEGF) injections in the previous 6 months: central macular thickness greater than 300 μm by spectral-domain optical coherence tomography (SD-OCT), reduction of retinal thickness by less than 10% of baseline retinal thickness, or suboptimal visual improvement (failure to gain at least 3 lines on the Snellen chart).

  • The subjects included in the research will undergo the following tests and investigations:

    1. Visual acuity testing (uncorrected and best corrected).
    2. Intra ocular pressure (IOP) by applanation tonometry.
    3. Anterior segment examination by slit lamp
    4. Posterior segment examination by indirect ophthalmoscope and 78 D lens
    5. Spectral domain Optical coherence tomography (OCT).
    6. Ocular fundus photography and fluorescein angiography.
  • Exclusion criteria will be:

    1. Previous intraocular surgery (except cataract surgery done more than 6 months before the study).
    2. Coincident retinal pathology as choroidal neovascular membrane and age related macular degeneration.
    3. Previous laser photocoagulation.
    4. Intravitreal injection of triamcinolone acetonide.
    5. Prior ocular inflammation.
    6. The presence of retinal degeneration.
    7. Patients who didnot complete 6 months of follow up

Injection technique:

Preoperative preparation:

  1. Preoperative control of (Diabetes Mellitus)DM is essential before injection.
  2. Informed consent was obtained according to the ethical committee after discussing extensively with each patient about the benefits, risks and possible side effects of the procedure .
  3. The patient was prepared by topical fluoroquinolone eye drops (Moxifloxacin hydrochloride 0.5% Vigamox ,Alcon, USA) 4 times daily for three days before injection.

All patients were dilated before suprachoroidal injection of Triamcinolone Acetonide (SCTA) and indirect ophthalmoscope was placed at hand to examine fundus after injection.

We used 30 gauge 1cc insulin syringe. Other dispensable included 24 gauge intravenous branula. Needle was withdrawn from branula and branula was cut in such a way that only 1000um of insulin syringe was exposed from the edge of branula. 0.1 ml (4 mg ) of Triamcinolone Acetonide (TAAC) will be injected.

Post operative care:

After the injection topical antibiotic drop was applied (Moxifloxacin hydrochloride 0.5% Vigamox, Alcon, USA) and the eye was patched for several hours.

After surgery patients were instructed to administer antibiotic drop four times daily for 3 days .

  • Privacy of the patients must be guaranteed ,the data acquired from the participants will stay confidential through:

    1. Putting a code number to every patient, with hiding the patient's name.
    2. Photographing faces will not be needed.
    3. The results of the research will be only used in scientific aim.
  • Any unexpected risks like subconjunctival hemorrhage, syncope, vitreous hemorrhage, retinal detachment and endophthalmitis appeared during the course of the research will be cleared to the participants and the ethical committee on time.

Medical care will be carried out to complications like syncope, subconjunctival hemorrhage and surgical treatment by pars plana vitrectomy will be done in case of occurrence of vitreous hemorrhage, retinal detachment or endophthalmitis.

02

Conditions studied

  • Retinal Edema

Keywords

  • macular edema
03

In context

Papilledema

29 studies on the registry are indexed under Papilledema; 7 are open to participants now.

This study's planned enrollment of 100 is above the median of 50 across 19 interventional studies indexed under Papilledema.

Browse Papilledema studies →

Lead sponsor

Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients fulfilling one or more of the following criteria will be considered to have resistant DME after at least 3 consecutive monthly anti VEGF injections in the previous 6 months:
  • Central macular thickness greater than 300 μm by spectral-domain optical coherence tomography (SD-OCT).
  • Reduction of retinal thickness by less than 10% of baseline retinal thickness.
  • Suboptimal visual improvement (failure to gain at least 3 lines on the Snellen chart) and patients with recent onset central retinal vein occlusion less than 3 months.

Exclusion criteria

Exclusion Criteria:

  • Previous intraocular surgery (except cataract surgery done more than 6 months before the study).
  • Coincident retinal pathology as choroidal neovascular membrane and age related macular degeneration.
  • Previous laser photocoagulation.
  • Intravitreal injection of triamcinolone acetonide.
  • Prior ocular inflammation.
  • The presence of retinal degeneration.
  • Patients who didnot complete 6 months of follow up
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    resistant diabetic macular edema and central retinal vein occlusion

    * Prospective non randomized interventional study on 60 eyes of 40 patients with previously diagnosed macular edema secondary to type 1 or 2 diabetes mellitus will be included. * The study will be conducted from January 2021 to June 2021. * For transition to suprachoroidal injection of TAAC a diagnosis of resistant DME is required. Cases with recent onset central retinal vein occlusion less than 2 months duration will be included

    Drug: Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1

Interventions

  • DrugTriamcinolone Acetonide 40Mg/Ml Inj,Susp_#1

    Drug page: Triamcinolone AcetonideStudies of Triamcinolone AcetonideTriamcinolone Acetonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion

    Also known as: 30 gauge syringe with 24 gauge cannula

06

What researchers measure

Primary outcomes

  1. Improvement of central macular thickness

    Reduction of the central macular thickness below 300 um

    Time frame: 1 month

Secondary outcomes

  1. improved vision

    Improvement of best corrected visual acuity

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Publications

  • Nawar AE. Modified Microneedle for Suprachoroidal Injection of Triamcinolone Acetonide Combined with Intravitreal Injection of Ranibizumab in Branch Retinal Vein Occlusion Patients. Clin Ophthalmol. 2022 Apr 19;16:1139-1151. doi: 10.2147/OPTH.S361636. eCollection 2022. PubMed 35469288 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2024; primary completion for Dec 2024, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2020
First posted
Dec 30, 2020
StartEst.
Dec 1, 2024
Primary completionEst.
Dec 1, 2024
CompletionEst.
Feb 1, 2025
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04690608
Lead sponsor
Tanta University
Responsible party
Amin El Sayed Nawar (Lecturer Of Ophthalmology, Tanta university, Tanta University) — Principal investigator
First posted
Dec 30, 2020
Start date
Dec 1, 2024 (estimated)
Primary completion
Dec 1, 2024 (estimated)
Completion
Feb 1, 2025 (estimated)
Last update
Mar 5, 2024

Study contacts

Amin E Nawar, Lecturer
Contact
nawar20012002@gmail.com
00201140095692
Esraa A Mohammad, L;ecturer
Contact
esraaaziz87@gmail.com
00201201500472
Amin E Nawar, Lecturer
principal investigator · Faculty of medicine, Tanta University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion